Annovis Bio, Inc.
ANVSDrugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 11, 2026
7dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
ANVS Earnings Report
EPS Est: $-0.44 | FQ end 2026-06
How ANVS's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
buntanetap/posiphen | Phase 3 | Parkinson's Disease, Idiopathic | - | - |
Posiphen | Phase 2 | Alzheimer's Disease | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Annovis Bio, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Annovis Bio, Inc.'s (ANVS) pipeline across Phase 3, Phase 2. Its lead program is buntanetap/posiphen (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Annovis Bio, Inc.'s next FDA catalyst?→
Annovis Bio, Inc.'s (ANVS) next tracked catalyst is a Earnings expected August 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ANVS biotech catalysts?→
Add ANVS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Annovis Bio, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.